Dolutegravir in antiretroviral-naive adults with HIV-1: 96-week results from a randomized dose-ranging study

Hans Jürgen Stellbrink,Jacques Reynes,Adriano Lazzarin,Eugene Voronin,Federico Pulido,Franco Felizarta,Steve Almond,Marty St. Clair,Nancy Flack,Sherene Min

Dolutegravir in antiretroviral-naive adults with HIV-1: 96-week results from a randomized dose-ranging study

2013

Hans Jürgen Stellbrink
Jacques Reynes
Adriano Lazzarin
Eugene Voronin
Federico Pulido
Franco Felizarta
Steve Almond
Marty St. Clair
Nancy Flack
Sherene Min

Objective: To evaluate the efficacy and safety/tolerability of dolutegravir (DTG, S/GSK1349572), a potent inhibitor of HIV integrase, through the full 96 weeks of the SPRING-1 study.

Keywords:

Dolutegravir
Medicine
Virology
Dose-ranging study
ANTIRETROVIRAL AGENTS
Integrase
Pharmacology
Tolerability
HIV Integrase Inhibitors
Viral load
human immunodeficiency virus
antiretroviral naive

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

100

Citations